MD Magazine (7/14, Walter) reports, “While all signs point to esketamine as an effective medication for those suffering from treatment-resistant depression, the cost might be too high to really make a dent in this patient population,” investigators concluded in a study that “estimated the cost-effectiveness of esketamine to treat patients with treatment-resistant depression.” The modeling study revealed that “ultimately, it is unlikely that esketamine ends up as a cost-effective option to treat patients with treatment-resistant depression in the US unless prices for esketamine decrease by more than 40%.” The findings were published online July 7 in Psychiatric Services, a publication of the American Psychiatric Association.
Related Links:
— “Esketamine Effective and Costly Treating Treatment-Resistant Depression, “Kenny Walter, MD Magazine, July 14, 2020